MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas
- PMID: 27277032
- PMCID: PMC4866963
- DOI: 10.1118/1.4948668
MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas
Abstract
Purpose: Imaging biomarker research focuses on discovering relationships between radiological features and histological findings. In glioblastoma patients, methylation of the O(6)-methylguanine methyltransferase (MGMT) gene promoter is positively correlated with an increased effectiveness of current standard of care. In this paper, the authors investigate texture features as potential imaging biomarkers for capturing the MGMT methylation status of glioblastoma multiforme (GBM) tumors when combined with supervised classification schemes.
Methods: A retrospective study of 155 GBM patients with known MGMT methylation status was conducted. Co-occurrence and run length texture features were calculated, and both support vector machines (SVMs) and random forest classifiers were used to predict MGMT methylation status.
Results: The best classification system (an SVM-based classifier) had a maximum area under the receiver-operating characteristic (ROC) curve of 0.85 (95% CI: 0.78-0.91) using four texture features (correlation, energy, entropy, and local intensity) originating from the T2-weighted images, yielding at the optimal threshold of the ROC curve, a sensitivity of 0.803 and a specificity of 0.813.
Conclusions: Results show that supervised machine learning of MRI texture features can predict MGMT methylation status in preoperative GBM tumors, thus providing a new noninvasive imaging biomarker.
Figures
Similar articles
-
Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.J Magn Reson Imaging. 2018 May;47(5):1380-1387. doi: 10.1002/jmri.25860. Epub 2017 Sep 19. J Magn Reson Imaging. 2018. PMID: 28926163
-
Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.Eur Radiol. 2018 Sep;28(9):3640-3650. doi: 10.1007/s00330-017-5302-1. Epub 2018 Mar 21. Eur Radiol. 2018. PMID: 29564594
-
Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.BMC Cancer. 2018 Feb 21;18(1):215. doi: 10.1186/s12885-018-4114-2. BMC Cancer. 2018. PMID: 29467012 Free PMC article.
-
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.World J Surg Oncol. 2016 Oct 12;14(1):261. doi: 10.1186/s12957-016-1012-4. World J Surg Oncol. 2016. PMID: 27733166 Free PMC article. Review.
-
The significance of MGMT methylation in Glioblastoma Multiforme prognosis.J Pak Med Assoc. 2018 Jul;68(7):1137-1139. J Pak Med Assoc. 2018. PMID: 30317322 Review.
Cited by 57 articles
-
Brain tumor IDH, 1p/19q, and MGMT molecular classification using MRI-based deep learning: an initial study on the effect of motion and motion correction.J Med Imaging (Bellingham). 2022 Jan;9(1):016001. doi: 10.1117/1.JMI.9.1.016001. Epub 2022 Jan 27. J Med Imaging (Bellingham). 2022. PMID: 35118164
-
Radiomics for precision medicine in glioblastoma.J Neurooncol. 2022 Jan;156(2):217-231. doi: 10.1007/s11060-021-03933-1. Epub 2022 Jan 12. J Neurooncol. 2022. PMID: 35020109 Review.
-
Multiparametric radiomic tissue signature and machine learning for distinguishing radiation necrosis from tumor progression after stereotactic radiosurgery.Neurooncol Adv. 2021 Oct 25;3(1):vdab150. doi: 10.1093/noajnl/vdab150. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34901857 Free PMC article.
-
Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.Front Immunol. 2021 Nov 25;12:790674. doi: 10.3389/fimmu.2021.790674. eCollection 2021. Front Immunol. 2021. PMID: 34899760 Free PMC article. Review.
-
AI and High-Grade Glioma for Diagnosis and Outcome Prediction: Do All Machine Learning Models Perform Equally Well?Front Oncol. 2021 Nov 23;11:601425. doi: 10.3389/fonc.2021.601425. eCollection 2021. Front Oncol. 2021. PMID: 34888226 Free PMC article.
References
-
- Stupp R., Mason W. P., van den Bent M. J., Weller M., Fisher B., Taphoorn M. J., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., and European Organisation for Research and Treatment of Cancer, Brain Tumor, and Radiotherapy Groups, and National Cancer Institute of Canada Clinical Trials Group, āRadiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,ā N. Engl. J. Med. 352, 987ā996 (2005).10.1056/NEJMoa043330 - DOI - PubMed
-
- Rivera A. L., Pelloski C. E., Gilbert M. R., Colman H., De La Cruz C., Sulman E. P., Bekele B. N., and Aldape K. D., āMGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma,ā Neuro Oncol. 12, 116ā121 (2010).10.1093/neuonc/nop020 - DOI - PMC - PubMed
MeSH terms
Substances
Grant support
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
